In vivo, selective depletion of YAP1 in ECM-CAFs led to slower tumor progression, increased infiltration of CD8+; T-cells, and reduced collagen deposition in prostate cancer mouse models [44]. This evidence concerns the gene YAP1 and prostate carcinoma.